Standard

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. / Stalman, Eileen W.; Wieske, Luuk; van Dam, Koos P. J. et al.

In: Annals of the rheumatic diseases, Vol. 81, No. 12, 222904, 05.09.2022, p. 1757-1766.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Stalman, EW, Wieske, L, van Dam, KPJ, Kummer, LY, van Kempen, ZLE, Killestein, J, Volkers, AG, Tas, SW, Boekel, L, Wolbink, GJ, van der Kooi, AJ, Raaphorst, J, Löwenberg, M, Takkenberg, RB, D'Haens, GRAM, Spuls, PI, Bekkenk, MW, Musters, AH, Post, NF, Bosma, AL, Hilhorst, ML, Vegting, Y, Bemelman, FJ, Voskuyl, AE, Broens, B, Parra Sanchez, A, van Els, CCACM, Wit, JD, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, JJGM, Ruiter, AM, van Ouwerkerk, L, van der Woude, D, Allaart, CF, Teng, OYK, van Paassen, P, Busch, MH, Jallah, PBP, Brusse, E, van Doorn, PA, Baars, AE, Hijnen, DJ, Schreurs, CRG, van der Pol, WL, Goedee, HS, Steenhuis, M, Keijzer, S, Keijser, JBD, Boogaard, A, Cristianawati, O, ten Brinke, A, Verstegen, NJM, Zwinderman, KAH, Rispens, T, van Ham, SM, Kuijpers, TW & Eftimov, F 2022, 'Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases', Annals of the rheumatic diseases, vol. 81, no. 12, 222904, pp. 1757-1766. https://doi.org/10.1136/ard-2022-222904

APA

Stalman, E. W., Wieske, L., van Dam, K. P. J., Kummer, L. Y., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., Wolbink, G. J., van der Kooi, A. J., Raaphorst, J., Löwenberg, M., Takkenberg, R. B., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., Post, N. F., ... Eftimov, F. (2022). Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Annals of the rheumatic diseases, 81(12), 1757-1766. [222904]. https://doi.org/10.1136/ard-2022-222904

Vancouver

Stalman EW, Wieske L, van Dam KPJ, Kummer LY, van Kempen ZLE, Killestein J et al. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Annals of the rheumatic diseases. 2022 Sep 5;81(12):1757-1766. 222904. Epub 2022. doi: 10.1136/ard-2022-222904

Author

Stalman, Eileen W. ; Wieske, Luuk ; van Dam, Koos P. J. et al. / Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. In: Annals of the rheumatic diseases. 2022 ; Vol. 81, No. 12. pp. 1757-1766.

BibTeX

@article{9567356754cb4d8db93e88e8977ca381,
title = "Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases",
abstract = "Objectives: To compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls, and to investigate determinants for breakthrough infections. Methods: Data were used from an ongoing national prospective multicentre cohort study on SARS-CoV-2 vaccination responses in patients with IMID in the Netherlands (Target-to-B! (T2B!) study). Patients wih IMID on immunosuppressants and controls (patients with IMID not on immunosuppressants and healthy controls) who completed primary immunisation were included. The observation period was between 1 January 2022 and 1 April 2022, during which the SARS-CoV-2 omicron (BA.1 and BA.2 subvariant) was dominant. A SARS-CoV-2 breakthrough infection was defined as a reported positive PCR and/or antigen test at least 14 days after primary immunisation. A multivariate logistic regression model was used to investigate determinants. Results: 1593 patients with IMID on immunosuppressants and 579 controls were included. The cumulative incidence of breakthrough infections was 472/1593 (29.6%; 95% CI 27% to 32%) in patients with IMID on immunosuppressants and 181/579 (31.3%; 95% CI 28% to 35%) in controls (p=0.42). Three (0.5%) participants had severe disease. Seroconversion after primary immunisation (relative risk, RR 0.71; 95% CI 0.52 to 0.96), additional vaccinations (RR 0.61; 95% CI 0.49 to 0.76) and a prior SARS-CoV-2 infection (RR 0.60; 95% CI 0.48 to 0.75) were associated with decreased risk of breakthrough infection. Conclusions: The cumulative incidence of reported SARS-CoV-2 omicron breakthrough infections was high, but similar between patients with IMID on immunosuppressants and controls, and disease severity was mostly mild. Additional vaccinations and prior SARS-CoV-2 infections may reduce the incidence of breakthrough infections.",
keywords = "Autoimmune Diseases, Autoimmunity, Covid-19, Vaccination",
author = "Stalman, {Eileen W.} and Luuk Wieske and {van Dam}, {Koos P. J.} and Kummer, {Laura Y.} and {van Kempen}, {Zo{\'e} L. E.} and Joep Killestein and Volkers, {Adriaan G.} and Tas, {Sander W.} and Laura Boekel and Wolbink, {Gertjan J.} and {van der Kooi}, {Anneke J.} and Joost Raaphorst and Mark L{\"o}wenberg and Takkenberg, {R. Bart} and D'Haens, {Geert R. A. M.} and Spuls, {Phyllis I.} and Bekkenk, {Marcel W.} and Musters, {Annelie H.} and Post, {Nicoline F.} and Bosma, {Angela L.} and Hilhorst, {Marc L.} and Yosta Vegting and Bemelman, {Frederique J.} and Voskuyl, {Alexandre E.} and Bo Broens and {Parra Sanchez}, Agner and {van Els}, {C. cile A. C. M.} and Wit, {Jelle De} and Abraham Rutgers and {de Leeuw}, Karina and Barbara Horv{\'a}th and Verschuuren, {Jan J. G. M.} and Ruiter, {Annabel M.} and {van Ouwerkerk}, Lotte and {van der Woude}, Diane and Allaart, {C. F.} and Teng, {Onno Y. K.} and {van Paassen}, Pieter and Busch, {Matthias H.} and Jallah, {Papay B. P.} and Esther Brusse and {van Doorn}, {Pieter A.} and Baars, {Ad{\'a}ja Elisabeth} and Hijnen, {Dirk Jan} and Schreurs, {Corine R. G.} and {van der Pol}, {W. Ludo} and Goedee, {H. Stephan} and Maurice Steenhuis and Sofie Keijzer and Keijser, {Jim B. D.} and Arend Boogaard and Olvi Cristianawati and {ten Brinke}, Anja and Verstegen, {Niels J. M.} and Zwinderman, {Koos A. H.} and Theo Rispens and {van Ham}, {S. Marieke} and Kuijpers, {Taco W.} and Filip Eftimov",
note = "Funding Information: We thank ZonMw (The Netherlands Organization for Health Research and Development, grant 10430072010007) for the funding of the study and the T2B partners, including the patient groups, and Health Holland for the support in this study. This collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. We also thank E P Moll van Charante (Department of Public and Occupational Health and Department of General Practice, Amsterdam UMC, University of Amsterdam; and Amsterdam Public Health Research Institute, Amsterdam, Netherlands), J A Bogaards (Department of Epidemiology and Data Science, Amsterdam UMC), and R A Scholte (Clinical Research Unit, Amsterdam UMC, University of Amsterdam) for their guidance in the data safety monitoring board. Publisher Copyright: {\textcopyright} 2022 BMJ Publishing Group. All rights reserved.",
year = "2022",
month = sep,
day = "5",
doi = "10.1136/ard-2022-222904",
language = "English",
volume = "81",
pages = "1757--1766",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "12",

}

RIS

TY - JOUR

T1 - Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

AU - Stalman, Eileen W.

AU - Wieske, Luuk

AU - van Dam, Koos P. J.

AU - Kummer, Laura Y.

AU - van Kempen, Zoé L. E.

AU - Killestein, Joep

AU - Volkers, Adriaan G.

AU - Tas, Sander W.

AU - Boekel, Laura

AU - Wolbink, Gertjan J.

AU - van der Kooi, Anneke J.

AU - Raaphorst, Joost

AU - Löwenberg, Mark

AU - Takkenberg, R. Bart

AU - D'Haens, Geert R. A. M.

AU - Spuls, Phyllis I.

AU - Bekkenk, Marcel W.

AU - Musters, Annelie H.

AU - Post, Nicoline F.

AU - Bosma, Angela L.

AU - Hilhorst, Marc L.

AU - Vegting, Yosta

AU - Bemelman, Frederique J.

AU - Voskuyl, Alexandre E.

AU - Broens, Bo

AU - Parra Sanchez, Agner

AU - van Els, C. cile A. C. M.

AU - Wit, Jelle De

AU - Rutgers, Abraham

AU - de Leeuw, Karina

AU - Horváth, Barbara

AU - Verschuuren, Jan J. G. M.

AU - Ruiter, Annabel M.

AU - van Ouwerkerk, Lotte

AU - van der Woude, Diane

AU - Allaart, C. F.

AU - Teng, Onno Y. K.

AU - van Paassen, Pieter

AU - Busch, Matthias H.

AU - Jallah, Papay B. P.

AU - Brusse, Esther

AU - van Doorn, Pieter A.

AU - Baars, Adája Elisabeth

AU - Hijnen, Dirk Jan

AU - Schreurs, Corine R. G.

AU - van der Pol, W. Ludo

AU - Goedee, H. Stephan

AU - Steenhuis, Maurice

AU - Keijzer, Sofie

AU - Keijser, Jim B. D.

AU - Boogaard, Arend

AU - Cristianawati, Olvi

AU - ten Brinke, Anja

AU - Verstegen, Niels J. M.

AU - Zwinderman, Koos A. H.

AU - Rispens, Theo

AU - van Ham, S. Marieke

AU - Kuijpers, Taco W.

AU - Eftimov, Filip

N1 - Funding Information: We thank ZonMw (The Netherlands Organization for Health Research and Development, grant 10430072010007) for the funding of the study and the T2B partners, including the patient groups, and Health Holland for the support in this study. This collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. We also thank E P Moll van Charante (Department of Public and Occupational Health and Department of General Practice, Amsterdam UMC, University of Amsterdam; and Amsterdam Public Health Research Institute, Amsterdam, Netherlands), J A Bogaards (Department of Epidemiology and Data Science, Amsterdam UMC), and R A Scholte (Clinical Research Unit, Amsterdam UMC, University of Amsterdam) for their guidance in the data safety monitoring board. Publisher Copyright: © 2022 BMJ Publishing Group. All rights reserved.

PY - 2022/9/5

Y1 - 2022/9/5

N2 - Objectives: To compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls, and to investigate determinants for breakthrough infections. Methods: Data were used from an ongoing national prospective multicentre cohort study on SARS-CoV-2 vaccination responses in patients with IMID in the Netherlands (Target-to-B! (T2B!) study). Patients wih IMID on immunosuppressants and controls (patients with IMID not on immunosuppressants and healthy controls) who completed primary immunisation were included. The observation period was between 1 January 2022 and 1 April 2022, during which the SARS-CoV-2 omicron (BA.1 and BA.2 subvariant) was dominant. A SARS-CoV-2 breakthrough infection was defined as a reported positive PCR and/or antigen test at least 14 days after primary immunisation. A multivariate logistic regression model was used to investigate determinants. Results: 1593 patients with IMID on immunosuppressants and 579 controls were included. The cumulative incidence of breakthrough infections was 472/1593 (29.6%; 95% CI 27% to 32%) in patients with IMID on immunosuppressants and 181/579 (31.3%; 95% CI 28% to 35%) in controls (p=0.42). Three (0.5%) participants had severe disease. Seroconversion after primary immunisation (relative risk, RR 0.71; 95% CI 0.52 to 0.96), additional vaccinations (RR 0.61; 95% CI 0.49 to 0.76) and a prior SARS-CoV-2 infection (RR 0.60; 95% CI 0.48 to 0.75) were associated with decreased risk of breakthrough infection. Conclusions: The cumulative incidence of reported SARS-CoV-2 omicron breakthrough infections was high, but similar between patients with IMID on immunosuppressants and controls, and disease severity was mostly mild. Additional vaccinations and prior SARS-CoV-2 infections may reduce the incidence of breakthrough infections.

AB - Objectives: To compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls, and to investigate determinants for breakthrough infections. Methods: Data were used from an ongoing national prospective multicentre cohort study on SARS-CoV-2 vaccination responses in patients with IMID in the Netherlands (Target-to-B! (T2B!) study). Patients wih IMID on immunosuppressants and controls (patients with IMID not on immunosuppressants and healthy controls) who completed primary immunisation were included. The observation period was between 1 January 2022 and 1 April 2022, during which the SARS-CoV-2 omicron (BA.1 and BA.2 subvariant) was dominant. A SARS-CoV-2 breakthrough infection was defined as a reported positive PCR and/or antigen test at least 14 days after primary immunisation. A multivariate logistic regression model was used to investigate determinants. Results: 1593 patients with IMID on immunosuppressants and 579 controls were included. The cumulative incidence of breakthrough infections was 472/1593 (29.6%; 95% CI 27% to 32%) in patients with IMID on immunosuppressants and 181/579 (31.3%; 95% CI 28% to 35%) in controls (p=0.42). Three (0.5%) participants had severe disease. Seroconversion after primary immunisation (relative risk, RR 0.71; 95% CI 0.52 to 0.96), additional vaccinations (RR 0.61; 95% CI 0.49 to 0.76) and a prior SARS-CoV-2 infection (RR 0.60; 95% CI 0.48 to 0.75) were associated with decreased risk of breakthrough infection. Conclusions: The cumulative incidence of reported SARS-CoV-2 omicron breakthrough infections was high, but similar between patients with IMID on immunosuppressants and controls, and disease severity was mostly mild. Additional vaccinations and prior SARS-CoV-2 infections may reduce the incidence of breakthrough infections.

KW - Autoimmune Diseases

KW - Autoimmunity

KW - Covid-19

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85137856243&partnerID=8YFLogxK

U2 - 10.1136/ard-2022-222904

DO - 10.1136/ard-2022-222904

M3 - Article

C2 - 36357161

VL - 81

SP - 1757

EP - 1766

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

SN - 0003-4967

IS - 12

M1 - 222904

ER -

ID: 26113476